Remote Digital Diagnostics

​

Point of care diagnostic tests such as dipstick or lateral flow tests are analogue and siloed. They rely on an individual to read and interpret a visual result (typically lines, dots or colours) and to manually record the result. Each of these is subject to human error. The results remain unconnected unless manually entered into a digital platform of some kind.

​

Part of UnifAI's mission is to develop AI solutions which improve the health and wellbeing of people. We have developed a powerful AI solution to turn a range of point of care medical tests into connected, digital tests. Our approach is to:

​

• Use a simple smartphone app which uses the camera phone to capture an image of the completed test

• Integrate the app with UnifAI's cloud-based platform

• Train our proprietary AI to read and interpret the test result - more accurately than trained medical staff

​

UnifAI has worked with InnovateUK to develop this solution for COVID-19 Lateral Flow Tests, and in January 2022 we were delighted that our Digital Reader has been authorised for use in the UK and Northern Ireland.

 

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the UnifAI Technology Digital Reader for Special Use as a medical device for the accurate reading of COVID-19 lateral flow diagnostic tests.  The Special Use derogation currently covers Innova, ACON and Orient Gene lateral flow tests which are in use in the NHS Test & Trace programme, and MP Bio lateral flow tests. Further tests expected to be added.

​

This is an exciting achievement, and UnifAI plans to develop this capability for a wider range of remote diagnostics and telehealth solutions. 

​

UK Health Security Agency (UKHSA)

​

In April 2022 UnifAI Technology won a competitive tender to become the sole AI Digital Reader provider to the UK Health Security Agency (UKHSA).

​

​